We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
- Authors
Lennon, Siân; Barton, Claire; Banken, Ludger; Gianni, Luca; Marty, Michel; Baselga, José; Leyland-Jones, Brian
- Abstract
Trastuzumab is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2). Trastuzumab alone or in combination with chemotherapy has been shown to be effective in patients with HER2-positive early and metastatic breast cancer. The extracellular domain (ECD) of the HER2 protein may be shed into the serum and is detectable using an enzyme-linked immunosorbent assay. Correlations have been reported between raised baseline ECD levels and response to trastuzumab, suggesting that serum ECD levels may be useful in making treatment decisions in patients with HER2-positive breast cancer. We investigated this relationship, and also the effect of trastuzumab and chemotherapy on ECD levels, in patients with advanced breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 10, p1685
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.8351